LIFE SCIENCE  | 
PHYSICAL SCIENCE  | 
RESEARCH TOOLS  | 
SOFTWARE AND COPYRIGHT
TECHNOLOGY COMMERCIALIZATION HOME  | 
SEARCH
Search Results - Oncology
32
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Discovery of Well Defined Sulfated Glycopolymers as Specific Heparanase Inhibitors for Cancer Therapeutics
The remodeling of the extracellular matrix has been shown to be highly upregulated in cancer and inflammation and is critically linked to the processes of invasion and metastasis. The finding that heparanase is elevated in a wide variety of tumor types and is subsequently linked to the development of pathological processes has led to an explosion of...
Published: 12/2/2020
|
Inventor(s):
Hein Nguyen
,
Ravi Loka
,
Eric Sletten
,
Israel Vlodavsky
Keywords(s):
Cancer
,
Cancer Therapies
,
Pharmaceuticals
,
Therapeutics
Category(s):
Life Science
,
Oncology
,
Pharmaceuticals
,
Therapeutics
A method to induce ferroptosis and to downregulate androgen receptor/androgen receptor splice variant in prostate cancer cells
Prostate cancer (PCa) effects approximately three million men in the United States every year. About 10-20% of the cases of prostate cancer are castrate-resistant prostate cancer (CRPC). This form of PCa is highly resistant to what Is known as androgen depletion therapy and is often fatal. All types of PCa are sensitive to androgen receptor signaling...
Published: 10/26/2023
|
Inventor(s):
Zhihui Qin
,
Liping Xu
Keywords(s):
Anti-cancer
,
Cancer
,
Cancer Therapies
,
Drug Delivery
,
Drug Target
,
Prostate Cancer
Category(s):
Medical
,
Diseases
,
Drug Discovery
,
Pharmaceuticals
,
Oncology
Identification of Galeterone's mechanism of action leading to novel treatment therapies for castrate resistant prostate cancer (CRPC)
Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (HRPC), is a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT). The need for effective therapies for these difficult to treat cancers is gaining prominence in the prostate cancer market. The global CRPC market is poised...
Published: 11/19/2020
|
Inventor(s):
Qingping Dou
,
Huanjie Yang
,
Elisabeth Heath
Keywords(s):
Category(s):
Life Science
,
Oncology
,
Pharmaceuticals
,
Receptors/targets
,
Process/Procedure
,
Small molecule
,
Therapeutics
Fc-folate conjugate for the treatment of triple negative breast cancer
Approximately 13% of women in the United States will develop breast cancer according to the American Cancer Society. That makes breast cancer the second leading cause of cancer death in women right behind lung cancer. Triple negative breast cancer (TNBC) represents about 10 – 20% of all breast cancers. Triple negative refers to cancer cells...
Published: 10/31/2024
|
Inventor(s):
Cecilia Speyer
Keywords(s):
Anti-cancer
,
Breast Cancer
,
Cancer
,
Cancer Therapies
Category(s):
Antibodies
,
Assays
,
Biology
,
Biomedical
,
Chemical Processing/Synthesis
,
Diseases
,
Drug Delivery
,
Life Science
,
Oncology
,
Protein/peptides
,
Receptors/targets
,
Small molecule
,
Therapeutics
Microfluidic platforms for live-cell imaging and bio/pathomimetic tissue models
Background:Methodologies to image and quantify tissue models using high-content analysis (HCI) and functional analyses of 3D avatars are needed as such avatars better recapitulate the phenotype of pathobiological processes and better predict efficacy of, and resistance to, a wide variety of therapies. Furthermore, changes in morphometry, viability,...
Published: 2/14/2022
|
Inventor(s):
Bonnie Sloane
,
Kamiar Moin
,
Kyungmin Ji
,
Kingsley Osuala
,
Yong Xu
,
Hongen Tu
Keywords(s):
Category(s):
Specialty compounds
,
Research tools
,
Oncology
,
Microfluidics
,
Life Science
,
Instrumentation
,
Imaging
,
Diseases
,
Devices
,
Cell lines
Drugs that disrupt interactions between ELK1 and the androgen receptor to suppress growth of both early stage and castration resistant prostate cancer
Background:Prostate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone, continued disease progression generally represents a transition to the lethal variant. In...
Published: 10/22/2019
|
Inventor(s):
Manohar Ratnam
,
Rayna Rosati
,
Mugdha Patki
Keywords(s):
Category(s):
Life Science
,
Therapeutics
,
Oncology
,
Drug Discovery
,
Pharmaceuticals
Using nanotechnology to target aggressive cancers with a novel small molecule inhibitor of the DNA damage tolerance pathway
Background: Nanotechnology is emerging as a promising tool to target cancer cells. Gold nanoparticles (GNPs) are preferentially taken up by cancer cells when injected into the blood stream and their safety has been demonstrated in human clinical trials. WSU researchers have designed a unique nanoparticle conjugate that combines a GNP with a small molecule...
Published: 8/29/2018
|
Inventor(s):
Malathy Shekhar
,
Guangzhao Mao
,
Yanhua Zhang
Keywords(s):
Category(s):
Life Science
,
Oncology
,
Small molecule
,
Receptors/targets
,
Nano-based
,
Drug Delivery
,
Therapeutics
,
Diseases
An in vivo QQ-systemic protein delivery technology and applications
BackgroundThis invention contains a new composition of our researchers’ previously patented QQ-protein delivery technology and the in vivo applications of this protein delivery technology via systemic administered proteins for cancer diagnosis and therapy. Many proteins and peptides are used as highly specific and effective therapeutic agents....
Published: 11/9/2021
|
Inventor(s):
Jianjun Wang
,
Qianqian Li
,
Quan Jiang
,
Feng Jiang
,
Michael Chopp
Keywords(s):
Cancer Therapies
,
Drug Delivery
Category(s):
Diagnostics
,
Drug Delivery
,
Life Science
,
Oncology
,
Research tools
,
Therapeutics
A protein-induced In situ cell-conversion technology and applications
BackgroundCell reprogramming and trans-differentiation are techniques that convert somatic cells of individuals into either stem cells, including embryonic and adult stem cells (reprogramming) or the other type of somatic cells (trans-differentiation). These techniques are usually performed in the cell culture settings using viral gene delivery and...
Published: 11/9/2021
|
Inventor(s):
Jianjun Wang
,
Qianqian Li
,
Feng Jiang
,
Michael Chopp
,
Guojun Wu
Keywords(s):
Cancer Therapies
,
Drug Delivery
Category(s):
Drug Delivery
,
Life Science
,
Research tools
,
Oncology
Inhibitors of the ubiquitin E3 ligase BCA2 as anti-cancer therapeutic agents
Background:Breast cancer associated protein 2 (BCA2) is a ubiquitin E3 ligase found in invasive breast cancer. Studies have shown that by decreasing its activity, breast cancer cell growth and invasiveness are diminished. Targeting this ligase and inhibiting its activity could play a role in treatment of breast cancer. A molecular approach to inhibiting...
Published: 3/12/2018
|
Inventor(s):
Angelika Burger
,
Andrew Westwell
Keywords(s):
Analog or Analogue
,
Breast Cancer
,
Cancer
,
Disease
,
Drug Target
,
Enzyme
Category(s):
Diseases
,
Oncology
,
Therapeutics
,
Life Science
,
Research tools
1
2
3
4